BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 20858067)

  • 1. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK; Tyson DR
    Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
    Calvo KR; Liotta LA; Petricoin EF
    Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer biomarkers: knowing the present and predicting the future.
    Chatterjee SK; Zetter BR
    Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathways to personalized medicine for breast and prostate cancers: emerging diagnostic methods and prognostic biomarkers.
    Watson AP; Egland KA
    S D Med; 2010 Jul; 63(7):247-53. PubMed ID: 20666024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine.
    Honda K; Ono M; Shitashige M; Masuda M; Kamita M; Miura N; Yamada T
    Jpn J Clin Oncol; 2013 Feb; 43(2):103-9. PubMed ID: 23248327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers of prostate cancer.
    Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
    Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic methodologies and their application in colorectal cancer research.
    Ikonomou G; Samiotaki M; Panayotou G
    Crit Rev Clin Lab Sci; 2009; 46(5-6):319-42. PubMed ID: 19958217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
    Sardana G; Jung K; Stephan C; Diamandis EP
    J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B; Ball G; Rees R
    Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
    J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for prostate cancer detection.
    Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
    J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of proteomics in prostate cancer research: biomarker discovery and validation.
    Pin E; Fredolini C; Petricoin EF
    Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein mass spectra data analysis for clinical biomarker discovery: a global review.
    Roy P; Truntzer C; Maucort-Boulch D; Jouve T; Molinari N
    Brief Bioinform; 2011 Mar; 12(2):176-86. PubMed ID: 20534688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced proteomic technologies for cancer biomarker discovery.
    Wong SC; Chan CM; Ma BB; Lam MY; Choi GC; Au TC; Chan AS; Chan AT
    Expert Rev Proteomics; 2009 Apr; 6(2):123-34. PubMed ID: 19385940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revealing urologic diseases by proteomic techniques.
    Lee SW; Lee KI; Kim JY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 815(1-2):203-13. PubMed ID: 15652810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteome analysis of prostate cancer.
    Kuruma H; Egawa S; Oh-Ishi M; Kodera Y; Maeda T
    Prostate Cancer Prostatic Dis; 2005; 8(1):14-21. PubMed ID: 15477873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.